Drug intelligence / Profile preview

BV211

Development stage: Phase 1
Lead developer: Wuhan BravoVax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BV211 is a recombinant protein subunit vaccine being developed by Wuhan BravoVax Co., Ltd. for the prevention of herpes zoster (shingles) in adults. The vaccine is designed to elicit a targeted immune response against the varicella-zoster virus (VZV). It is currently in Phase I clinical development, with a randomized, observer-blinded study (NCT05718037) evaluating its safety, tolerability, and immunogenicity in healthy volunteers aged 30 to 70 years. As a recombinant biologic, BV211 represents a modern approach to shingles prevention, aiming to provide a safer and potentially more effective alternative to traditional live-attenuated vaccines, particularly for older populations.

Other names: recombinant zoster vaccineBravoVax herpes zoster vaccine

Beyond the preview

Go deeper on BV211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BV211.

Explore the full profile